Here, we show that the expression of HMGA2 confers broad protection to cancer cells treated with the clinically important TOP2‐targeting drugs Etop and Merb, leading to a significant reduction in genotoxic DSBs during the course of drug treatment. The gene discussed is HMGA2; the disease is cancer.